Western Blotting

LG Laura Le Gall
WD William J. Duddy
CM Cecile Martinat
VM Virginie Mariot
OC Owen Connolly
VM Vanessa Milla
EA Ekene Anakor
ZO Zamalou G. Ouandaogo
SM Stephanie Millecamps
JL Jeanne Lainé
UV Udaya Geetha Vijayakumar
SK Susan Knoblach
CR Cedric Raoul
OL Olivier Lucas
JL Jean Philippe Loeffler
PB Peter Bede
AB Anthony Behin
HB Helene Blasco
GB Gaelle Bruneteau
MA Maria Del Mar Amador
DD David Devos
AH Alexandre Henriques
AH Adele Hesters
LL Lucette Lacomblez
PL Pascal Laforet
TL Timothee Langlet
PL Pascal Leblanc
NF Nadine Le Forestier
TM Thierry Maisonobe
VM Vincent Meininger
LR Laura Robelin
FS Francois Salachas
TS Tanya Stojkovic
GQ Giorgia Querin
JD Julie Dumonceaux
GB Gillian Butler Browne
JA Jose‐Luis González De Aguilar
SD Stephanie Duguez
PP Pierre Francois Pradat
ask Ask a question
Favorite

Extracted ALS and healthy vesicles were resuspended in lysis buffer (8 M urea; 2% SDS; 10 μL/mL protease inhibitor cocktail), and protein was extracted from muscle biopsies using RIPA buffer. Extracted proteins were loaded into NuPage polyacrylamide 4–12% BisTris gels for electrophoresis under reducing conditions (Calnexin, Flotillin, ALIX, FUS, SOD1, TDP43, RPL5, and skeletal alpha‐actin) and non‐reducing conditions (CD63 and CD81). Transfer on polyvinylidene difluoride (PVDF) membrane was performed using the iBlot® Dry Blotting System (Life Technologies™) and upon transfer polyacrylamide gels were stained with Blue Coomassie Gel Code Blue Stain Reagent (LifeTechnologies™) to visualize proteins. Immunoblotting was carried out using the iBind™ Flex Western System and primary antibodies (refer to Table S2) with respective secondary antibodies (Goat anti‐Mouse HRP, Donkey anti‐Goat HRP, Goat anti‐Rabbit HRP). The signal was detected using the Amersham ECL™ Prime Western blotting Detection Reagent and the UVP ChemiDoc‐It2 Imager.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A